کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5561170 | 1562115 | 2017 | 22 صفحه PDF | دانلود رایگان |
- In this journal, we previously described our Population Health Impact Model.
- Using it we assess effects of introducing a hypothetical lower risk tobacco product.
- It is assumed to be introduced in 1990 with mortality effects studied over 20 years.
- A basic set of assumptions is studied, as well as a range of sensitivity analyses.
- Major and minor factors affecting the reduction in deaths are determined.
We use Population Health Impact Modelling to assess effects on tobacco prevalence and mortality of introducing a Reduced Risk Tobacco Product (RRP). Simulated samples start in 1990 with a US-representative smoking prevalence. Individual tobacco histories are updated annually until 2010 using estimated probabilities of switching between never/current/former smoking where the RRP is not introduced, with current users subdivided into cigarette/RRP/dual users where it is. RRP-related mortality reductions from lung cancer, IHD, stroke and COPD are derived from the histories and the assumed relative risks of the RRP.A basic analysis assumes a hypothetical RRP reduces effective dose 80% in users and 40% in dual users, with an uptake rate generating â¼10% RRP and â¼6% dual users among current users after 10 years. Sensitivity study changes in tobacco prevalence and mortality from varying effective doses, current smoking risks, quitting half-lives and rates of initiation, switching, re-initiation and cessation. They also study extreme situations (e.g. everyone using RRP), and investigate assumptions which might eliminate the RRP-related mortality reduction. The mortality reduction is proportional to the dose reduction, increasing rapidly with time of follow-up. Plausible increases in re-initiation or dual users' consumption, or decreased quitting by smokers would not eliminate the drop.
Journal: Regulatory Toxicology and Pharmacology - Volume 88, August 2017, Pages 192-213